All articles by mrinmoyee hazarika

mrinmoyee hazarika

ASLAN doses first subject in alopecia areata therapy trial

The trial will examine the efficacy and safety of farudodstat in patients who have lost at least 50% of their scalp hair.

Antengene gets FDA approval for Phase I trial of cancer drug

ATG-031 is a humanised anti-CD24 monoclonal antibody and is Antengene’s third drug candidate to enter clinical trials in the US.

PepGen obtains Health Canada approval to begin DMD therapy trial

The trial will investigate the safety, tolerability, pharmacokinetics and clinical assessments of PGN-EDO51.

Shionogi starts Phase I trial of Covid-19 antiviral in Japan

The trial will assess the pharmacokinetics, safety, and tolerability of S-892216 in healthy adults.

University of Southampton trial shows spironolactone’s potential for acne

Spironolactone has been used for treating high blood pressure for decades.

FDA approves Ultragenyx’s Angelman syndrome therapy trial protocol amendment

The amended protocol allows Ultragenyx to match dose ranges in the US with those being used in the cohorts outside of the US.

UK clears OCTP’s Phase I trial application of OCT461201

The trial aims to show the safety, tolerability and pharmacokinetics of OCT461201.

Netramark unveils ChatGPT-based clinical trial de-risking technology

NetraGPT consumes data on specific clinical trial patient subpopulations identified by NetraAI.

Transcenta reports positive data from trial of TST002 for BMD

The Phase I trial evaluated TST002 (Blosozumab) in Chinese postmenopausal women and elder men with reduced bone mineral density.

HiST Pharma receives FDA IND clearance for psoriasis vulgaris drug trial

TC Cream represents the world’s first botanical small-molecule drug for treating psoriasis vulgaris.